Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
Genentech in Phase III Trial of Drug for COVID-19 Pneumonia

Genentech in Phase III Trial of Drug for COVID-19 Pneumonia

  • Posted by ISPE Boston
  • On March 23, 2020

Genentech is working with the FDA to initiate a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the safety and efficacy of Actemra (tocilizumab) for hospitalized patients with severe COVID-19 pneumonia. This is the first global study of Actemra in this setting and is expected to begin enrolling in early April with a target of approximately 330 patients globally, including the U.S. The primary and secondary endpoints include clinical status, mortality, mechanical ventilation and intensive care unit (ICU) variables.

The trial is being conducted by Genentech in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR),

To date, there are several independent clinical trials exploring the efficacy and safety of Actemra for the treatment of patients with COVID-19 pneumonia. However, this new trial is vital because there are no well-controlled studies and limited published evidence on the safety or efficacy of Actemra in the treatment of patients suffering from COVID-19. In addition, Actemra is not currently approved for this use by any health authorities, including the FDA.

Actemra was the first humanized interleukin-6 (IL-6) receptor antagonist approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs) that did not provide enough relief. Actemra subcutaneous injection is also approved for the treatment of giant cell arteritis (GCA) and two forms of juvenile arthritis, among other conditions.

Actemra is part of a co-development agreement with Chugai Pharmaceutical Co. and has been approved in Japan since June 2005. Actemra is approved in the European Union, where it is known as RoActemra, and several other countries, including China, India, Brazil, Switzerland and Australia.

In addition to initiating this trial, Genentech parent Roche has received FDA Emergency Use Authorization for the cobas® SARS-CoV-2 Test to detect the novel virus that causes COVID-19 disease. (Source: Genentech Website, 18 March, 2020)

Share this
 

0 Comments

Leave Reply Cancel reply

Leave a Comment

Your email address will not be published. Required fields are marked *

Post Categories
  • Podcasts (1)
  • Industry Buzz (557)
  • Chapter News (536)
  • Knowledge & Training (79)
  • Students & YP (78)
  • Career Tools (13)
Get Updates via Email




Leaders Call for Donations of Supplies to Fight COVID-19

Previous thumb

Condensed List of COVID-19 Industry Resources from ISPE International Headquarters

Next thumb
Scroll
Follow Us
Search this Site
@2024 ISPE Boston Chapter. All rights reserved.